Roche (SIX:RO, ROG; OTCQX:RHHBY) has announced new positive two-year data from its TENAYA and LUCERNE studies of Vabysmo (faricimab) in neovascular or “wet” age-related macular degeneration (nAMD). Based on the study results, Roche estimates that more than 60% of people taking the drug could receive an injection of facrimab once every four months while achieving…